Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

Colbers A, Greupink R, Litjens C, Burger D, Russel FG.

Clin Pharmacokinet. 2016 Mar;55(3):381-96. doi: 10.1007/s40262-015-0325-8.

2.

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS.

Prinapori R, Di Biagio A.

Patient Prefer Adherence. 2015 Aug 24;9:1213-8. doi: 10.2147/PPA.S88490. Review.

3.

Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.

Greenblatt DJ, Harmatz JS.

Br J Clin Pharmacol. 2015 Sep;80(3):342-50. doi: 10.1111/bcp.12668. Review.

4.

Investigating the contribution of CYP2J2 to ritonavir metabolism in vitro and in vivo.

Kaspera R, Kirby BJ, Sahele T, Collier AC, Kharasch ED, Unadkat JD, Totah RA.

Biochem Pharmacol. 2014 Sep 1;91(1):109-18. doi: 10.1016/j.bcp.2014.06.020.

5.

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.

Xu L, Liu H, Murray BP, Callebaut C, Lee MS, Hong A, Strickley RG, Tsai LK, Stray KM, Wang Y, Rhodes GR, Desai MC.

ACS Med Chem Lett. 2010 May 17;1(5):209-13. doi: 10.1021/ml1000257.

6.

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.

Pandey KK.

HIV AIDS (Auckl). 2014 May 16;6:81-90. doi: 10.2147/HIV.S39178. Review.

7.
8.

A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.

Okello MO, Mishra S, Nishonov M, Mankowski MK, Russell JD, Wei J, Hogan PA, Ptak RG, Nair V.

Antiviral Res. 2013 Jun;98(3):365-72. doi: 10.1016/j.antiviral.2013.04.005.

9.

Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers.

Ancrenaz V, Déglon J, Samer C, Staub C, Dayer P, Daali Y, Desmeules J.

Basic Clin Pharmacol Toxicol. 2013 Feb;112(2):132-7. doi: 10.1111/j.1742-7843.2012.00932.x.

10.

Alcohol consumption effect on antiretroviral therapy and HIV-1 pathogenesis: role of cytochrome P450 isozymes.

Kumar S, Jin M, Ande A, Sinha N, Silverstein PS, Kumar A.

Expert Opin Drug Metab Toxicol. 2012 Nov;8(11):1363-75. doi: 10.1517/17425255.2012.714366. Review.

11.

Pharmacology of HIV integrase inhibitors.

Adams JL, Greener BN, Kashuba AD.

Curr Opin HIV AIDS. 2012 Sep;7(5):390-400. doi: 10.1097/COH.0b013e328356e91c. Review.

12.

Antiretroviral drugs: critical issues and recent advances.

Desai M, Iyer G, Dikshit RK.

Indian J Pharmacol. 2012 May;44(3):288-98. doi: 10.4103/0253-7613.96296.

13.

Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.

Tseng A, Foisy M, Hughes CA, Kelly D, Chan S, Dayneka N, Giguère P, Higgins N, Hills-Nieminen C, Kapler J, la Porte CJ, Nickel P, Park-Wyllie L, Quaia C, Robinson L, Sheehan N, Stone S, Sulz L, Yoong D.

Can J Hosp Pharm. 2012 Mar;65(2):125-45. No abstract available.

14.

Novel therapeutic strategies targeting HIV integrase.

Quashie PK, Sloan RD, Wainberg MA.

BMC Med. 2012 Apr 12;10:34. doi: 10.1186/1741-7015-10-34. Review.

15.

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.

Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE.

Clin Pharmacol Ther. 2012 May;91(5):881-8. doi: 10.1038/clpt.2011.323.

16.

Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings.

Lee JS, Calmy A, Andrieux-Meyer I, Ford N.

HIV AIDS (Auckl). 2012;4:5-15. doi: 10.2147/HIV.S20993.

17.

Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration.

Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM.

Br J Clin Pharmacol. 2010 Mar;69(3):262-70. doi: 10.1111/j.1365-2125.2009.03566.x. Erratum in: Br J Clin Pharmacol. 2010 May;69(5):571.

18.

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).

Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team..

J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac.

19.

Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, Zinny MA, Court MH.

Br J Clin Pharmacol. 2009 Dec;68(6):920-7. doi: 10.1111/j.1365-2125.2009.03545.x.

Supplemental Content

Support Center